Opioid Exposure Risk Intensifying For Generic Drug Makers

Business fundamentals took a back seat to opioid litigation in the second quarter for generic drug makers, including Teva, Mallinckrodt and Endo Pharmaceuticals.

Risk-ahead

Teva Pharmaceutical Industries Ltd.'s turnaround is uncertain, Mallinckrodt PLC's spin-out of its generics business is delayed, and Endo International PLC's stock is barely treading water. All three find themselves among generic drug makers that are under intensifying pressure due to their exposure to opioid litigation – an issue that is distracting from business fundamentals and other strategic challenges.

The stocks of all three companies are trading below $10, with Teva's stock price opening 8 Aug at $7.09, down...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Legal & IP

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.